Inter-BRCT linker is probably the most intolerant region of the BRCA1 BRCT domain

References

• Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1-2, 19–25. https://doi.org/10.1016/j.softx.2015.06.001
   Google Scholar
• Ahmed, S. S., Rifat, Z. T., Lohia, R., Campbell, A. J., Dunker, A. K., Rahman, M. S., & Iqbal, S. (2022). Characterization of intrinsically disordered regions in proteins informed by human genetic diversity. PLoS Computational Biology, 18(3), e1009911. https://doi.org/10.1371/journal.pcbi.1009911
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos, T., Pertesi, M., Konstantopoulou, I., Armaou, S., Kamakari, S., Nasioulas, G., Athanasiou, A., Dobrovic, A., Young, M.-A., Goldgar, D., Fountzilas, G., & Yannoukakos, D. (2008). G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: Evaluation of its pathogenicity and inferences on its genealogical history. Breast Cancer Research and Treatment, 110(2), 377–385. https://doi.org/10.1007/s10549-007-9729-y
   PubMed Web of Science ®Google Scholar
• Baer, R., & Ludwig, T. (2002). The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Current Opinion in Genetics & Development, 12(1), 86–91. https://doi.org/10.1016/s0959-437x(01)00269-6
   PubMed Web of Science ®Google Scholar
• Barsevick, A. M., Montgomery, S. V., Ruth, K., Ross, E. A., Egleston, B. L., Bingler, R., Malick, J., Miller, S. M., Cescon, T. P., & Daly, M. B. (2008). Intention to communicate BRCA1/BRCA2 genetic test results to the family. Journal of Family Psychology: JFP: Journal of the Division of Family Psychology of the American Psychological Association (Division 43), 22(2), 303–312. https://doi.org/10.1037/0893-3200.22.2.303
   PubMed Web of Science ®Google Scholar
• Berendsen, H. J., Postma, J. v., van Gunsteren, W. F., DiNola, A., & Haak, J. (1984). Molecular dynamics with coupling to an external bath. The Journal of Chemical Physics, 81(8), 3684–3690. https://doi.org/10.1063/1.448118
   Web of Science ®Google Scholar
• Brent, R., & Ptashne, M. (1985). A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor. Cell, 43(3 Pt 2), 729–736. https://doi.org/10.1016/0092-8674(85)90246-6
   PubMed Web of Science ®Google Scholar
• Brzovic, P. S., Meza, J., King, M.-C., & Klevit, R. E. (1998). The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain. The Journal of Biological Chemistry, 273(14), 7795–7799. https://doi.org/10.1074/jbc.273.14.7795
   PubMed Web of Science ®Google Scholar
• Brzovic, P. S., Meza, J. E., King, M.-C., & Klevit, R. E. (2001). BRCA1 RING domain cancer-predisposing mutations: Structural consequences and effects on protein-protein interactions. Journal of Biological Chemistry, 276(44), 41399–41406. https://doi.org/10.1074/jbc.M106551200
   PubMed Web of Science ®Google Scholar
• Chan, P. A., Duraisamy, S., Miller, P. J., Newell, J. A., McBride, C., Bond, J. P., Raevaara, T., Ollila, S., Nyström, M., Grimm, A. J., Christodoulou, J., Oetting, W. S., & Greenblatt, M. S. (2007). Interpreting missense variants: Comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Human Mutation, 28(7), 683–693. https://doi.org/10.1002/humu.20492
   PubMed Web of Science ®Google Scholar
• Chapman, M. S., & Verma, I. M. (1996). Transcriptional activation by BRCA1. Nature, 382(6593), 678–679. https://doi.org/10.1038/382678a0
   PubMed Web of Science ®Google Scholar
• Chun, S., & Fay, J. C. (2009). Identification of deleterious mutations within three human genomes. Genome Research, 19(9), 1553–1561. https://doi.org/10.1101/gr.092619.109
   PubMed Web of Science ®Google Scholar
• Clapperton, J. A., Manke, I. A., Lowery, D. M., Ho, T., Haire, L. F., Yaffe, M. B., & Smerdon, S. J. (2004). Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nature Structural & Molecular Biology, 11(6), 512–518. https://doi.org/10.1038/nsmb775
   PubMed Web of Science ®Google Scholar
• Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N⋅ log (N) method for Ewald sums in large systems. The Journal of Chemical Physics, 98(12), 10089–10092. https://doi.org/10.1063/1.464397
   Web of Science ®Google Scholar
• Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., Garber, J. E., Neuhausen, S. L., Matloff, E., Eeles, R., Pichert, G., Van T'veer, L., Tung, N., Weitzel, J. N., Couch, F. J., Rubinstein, W. S., Ganz, P. A., Daly, M. B., Olopade, O. I., … Rebbeck, T. R. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA, 304(9), 967–975. https://doi.org/10.1001/jama.2010.1237
   PubMed Web of Science ®Google Scholar
• Dong, C., Wei, P., Jian, X., Gibbs, R., Boerwinkle, E., Wang, K., & Liu, X. (2015). Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Human Molecular Genetics, 24(8), 2125–2137. https://doi.org/10.1093/hmg/ddu733
   PubMed Web of Science ®Google Scholar
• Dunker, A. K., Cortese, M. S., Romero, P., Iakoucheva, L. M., & Uversky, V. N. (2005). Flexible nets: The roles of intrinsic disorder in protein interaction networks. The FEBS Journal, 272(20), 5129–5148. https://doi.org/10.1111/j.1742-4658.2005.04948.x
   PubMed Web of Science ®Google Scholar
• Easton, D. F., Deffenbaugh, A. M., Pruss, D., Frye, C., Wenstrup, R. J., Allen-Brady, K., Tavtigian, S. V., Monteiro, A. N. A., Iversen, E. S., Couch, F. J., & Goldgar, D. E. (2007). A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer–predisposition genes. American Journal of Human Genetics, 81(5), 873–883. https://doi.org/10.1086/521032
   PubMed Web of Science ®Google Scholar
• Easton, D. F., Ford, D., & Bishop, D. T. (1995). Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. American Journal of Human Genetics, 56(1), 265–271.
   PubMed Web of Science ®Google Scholar
• Estojak, J., Brent, R., & Golemis, E. A. (1995). Correlation of two-hybrid affinity data with in vitro measurements. Molecular and Cellular Biology, 15(10), 5820–5829. https://doi.org/10.1128/MCB.15.10.5820
   PubMed Web of Science ®Google Scholar
• Fernandes, V. C., Golubeva, V. A., Di Pietro, G., Shields, C., Amankwah, K., Nepomuceno, T. C., de Gregoriis, G., Abreu, R. B. V., Harro, C., Gomes, T. T., Silva, R. F., Suarez-Kurtz, G., Couch, F. J., Iversen, E. S., Monteiro, A. N. A., & Carvalho, M. A. (2019). Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. The Journal of Biological Chemistry, 294(15), 5980–5992. https://doi.org/10.1074/jbc.RA118.005274
   PubMed Web of Science ®Google Scholar
• Friedman, L. S., Ostermeyer, E. A., Szabo, C. I., Dowd, P., Lynch, E. D., Rowell, S. E., & King, M.-C. (1994). Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nature Genetics, 8(4), 399–404. https://doi.org/10.1038/ng1294-399
   PubMed Web of Science ®Google Scholar
• Gaiser, O. J., Ball, L. J., Schmieder, P., Leitner, D., Strauss, H., Wahl, M., Kühne, R., Oschkinat, H., & Heinemann, U. (2004). Solution structure, backbone dynamics, and association behavior of the C-terminal BRCT domain from the breast cancer-associated protein BRCA1. Biochemistry, 43(51), 15983–15995. https://doi.org/10.1021/bi049550q
   PubMed Web of Science ®Google Scholar
• Golemis, E. G. J., & Brent, R. (1994). Two hybrid system/interaction traps. In Ausubel, F.M. and Struhl, K. (Eds), Current Protocols in Molecular Biology. John Wiley and Sons. 13.14.11–13.14.17
   Google Scholar
• Gussow, A. B., Petrovski, S., Wang, Q., Allen, A. S., & Goldstein, D. B. (2016). The intolerance to functional genetic variation of protein domains predicts the localization of pathogenic mutations within genes. Genome Biology, 17(1), 9. https://doi.org/10.1186/s13059-016-0869-4
   PubMed Web of Science ®Google Scholar
• Hayeck, T. J., Stong, N., Wolock, C. J., Copeland, B., Kamalakaran, S., Goldstein, D. B., & Allen, A. S. (2019). Improved pathogenic variant localization via a hierarchical model of sub-regional intolerance. American Journal of Human Genetics, 104(2), 299–309. https://doi.org/10.1016/j.ajhg.2018.12.020
   PubMed Web of Science ®Google Scholar
• Hayes, F., Cayanan, C., Barillá, D., Monteiro, A.N.A. (2000). Functional Assay for BRCA1: Mutagenesis of C-Terminal Region Reveals Critical Residues for Transcription Activation. Cancer Research, 60(9), 2411–2418.
   Google Scholar
• Hess, B., Bekker, H., Berendsen, H. J., & Fraaije, J. G. (1997). LINCS: A linear constraint solver for molecular simulations. Journal of Computational Chemistry, 18(12), 1463–1472. https://doi.org/10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Web of Science ®Google Scholar
• Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., & Pease, L. R. (1989). Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene, 77(1), 51–59. https://doi.org/10.1016/0378-1119(89)90358-2
   PubMed Web of Science ®Google Scholar
• Huang, J., & MacKerell, A. D. Jr, (2013). CHARMM36 all‐atom additive protein force field: Validation based on comparison to NMR data. Journal of Computational Chemistry, 34(25), 2135–2145. https://doi.org/10.1002/jcc.23354
   PubMed Web of Science ®Google Scholar
• Ioannidis, N. M., Rothstein, J. H., Pejaver, V., Middha, S., McDonnell, S. K., Baheti, S., Musolf, A., Li, Q., Holzinger, E., Karyadi, D., Cannon-Albright, L. A., Teerlink, C. C., Stanford, J. L., Isaacs, W. B., Xu, J., Cooney, K. A., Lange, E. M., Schleutker, J., Carpten, J. D., … Sieh, W. (2016). REVEL: An ensemble method for predicting the pathogenicity of rare missense variants. American Journal of Human Genetics, 99(4), 877–885. https://doi.org/10.1016/j.ajhg.2016.08.016
   PubMed Web of Science ®Google Scholar
• Jhuraney, A., Velkova, A., Johnson, R. C., Kessing, B., Carvalho, R. S., Whiley, P., Spurdle, A. B., Vreeswijk, M. P. G., Caputo, S. M., Millot, G. A., Vega, A., Coquelle, N., Galli, A., Eccles, D., Blok, M. J., Pal, T., van der Luijt, R. B., Santamariña Pena, M., Neuhausen, S. L., … Monteiro, A. N. (2015). BRCA1 Circos: A visualisation resource for functional analysis of missense variants. Journal of Medical Genetics, 52(4), 224–230. https://doi.org/10.1136/jmedgenet-2014-102766
   PubMed Web of Science ®Google Scholar
• King, M. C., Wieand, S., Hale, K., Lee, M., Walsh, T., Owens, K., Tait, J., Ford, L., Dunn, B. K., Costantino, J., Wickerham, L., Wolmark, N., & Fisher, B.. (2001). Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. Jama, 286(18), 2251–2256. https://doi.org/10.1001/jama.286.18.2251
   PubMed Web of Science ®Google Scholar
• Kumar, P., Henikoff, S., & Ng, P. C. (2009). Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nature Protocols, 4(7), 1073–1081. https://doi.org/10.1038/nprot.2009.86
   PubMed Web of Science ®Google Scholar
• Li, J., Zhang, J., Tang, W., Mizu, R. K., Kusumoto, H., XiangWei, W., Xu, Y., Chen, W., Amin, J. B., Hu, C., Kannan, V., Keller, S. R., Wilcox, W. R., Lemke, J. R., Myers, S. J., Swanger, S. A., Wollmuth, L. P., Petrovski, S., Traynelis, S. F., & Yuan, H. (2019). De novo GRIN variants in NMDA receptor M2 channel pore‐forming loop are associated with neurological diseases. Human Mutation, 40(12), 2393–2413. https://doi.org/10.1002/humu.23895
   PubMed Web of Science ®Google Scholar
• Lyra, P.C.M., Jr., Nepomuceno, T.C., de Souza, M.L.M., Machado, G.F., Veloso, M.F., Henriques, T.B., Dos Santos, D.Z., Ribeiro, I.G., Ribeiro, R.S., Rangel, L.B.A., Richardson, M., Iversen, E.S., Goldgar, D., Couch, F., Carvalho, M.A., Monteiro, A.N.A. (2021). Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance. Genetics in Medicine, 23, 306–315. https://doi.org/10.1038/s41436-020-00991-0
   Google Scholar
• Manke, I. A., Lowery, D. M., Nguyen, A., & Yaffe, M. B. (2003). BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science (New York, N.Y.), 302(5645), 636–639. https://doi.org/10.1126/science.1088877
   PubMed Web of Science ®Google Scholar
• Mathe, E., Olivier, M., Kato, S., Ishioka, C., Hainaut, P., & Tavtigian, S. V. (2006). Computational approaches for predicting the biological effect of p53 missense mutations: A comparison of three sequence analysis based methods. Nucleic Acids Research, 34(5), 1317–1325. https://doi.org/10.1093/nar/gkj518
   PubMed Web of Science ®Google Scholar
• Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., & Ding, W. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (New York, N.Y.), 266(5182), 66–71. https://doi.org/10.1126/science.7545954
   PubMed Web of Science ®Google Scholar
• Miller, M. P., & Kumar, S. (2001). Understanding human disease mutations through the use of interspecific genetic variation. Human Molecular Genetics, 10(21), 2319–2328. https://doi.org/10.1093/hmg/10.21.2319
   PubMed Web of Science ®Google Scholar
• Monteiro, A., August, A., & Hanafusa, H. (1997). Common BRCA1 variants and transcriptional activation. American Journal of Human Genetics, 61(3), 761–762. https://doi.org/10.1086/515515
   PubMed Web of Science ®Google Scholar
• Monteiro, A. N., August, A., & Hanafusa, H. (1996). Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proceedings of the National Academy of Sciences of the United States of America, 93(24), 13595–13599. https://doi.org/10.1073/pnas.93.24.13595
   PubMed Web of Science ®Google Scholar
• Ogden, K. K., Chen, W., Swanger, S. A., McDaniel, M. J., Fan, L. Z., Hu, C., Tankovic, A., Kusumoto, H., Kosobucki, G. J., Schulien, A. J., Su, Z., Pecha, J., Bhattacharya, S., Petrovski, S., Cohen, A. E., Aizenman, E., Traynelis, S. F., & Yuan, H. (2017). Molecular mechanism of disease-associated mutations in the pre-M1 helix of NMDA receptors and potential rescue pharmacology. PLoS Genetics, 13(1), e1006536. https://doi.org/10.1371/journal.pgen.1006536
   PubMed Web of Science ®Google Scholar
• Parrinello, M., & Rahman, A. (1981). Polymorphic transitions in single crystals: A new molecular dynamics method. Journal of Applied Physics, 52(12), 7182–7190. https://doi.org/10.1063/1.328693
   Web of Science ®Google Scholar
• Pérez-Palma, E., May, P., Iqbal, S., Niestroj, L.-M., Du, J., Heyne, H. O., Castrillon, J. A., O'Donnell-Luria, A., Nürnberg, P., Palotie, A., Daly, M., & Lal, D. (2020). Identification of pathogenic variant enriched regions across genes and gene families. Genome Research, 30(1), 62–71. https://doi.org/10.1101/gr.252601.119
   PubMed Web of Science ®Google Scholar
• Petrovski, S., Wang, Q., Heinzen, E. L., Allen, A. S., & Goldstein, D. B. (2013). Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genetics, 9(8), e1003709. https://doi.org/10.1371/journal.pgen.1003709
   PubMed Web of Science ®Google Scholar
• Ruffner, H., Joazeiro, C. A., Hemmati, D., Hunter, T., & Verma, I. M. (2001). Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proceedings of the National Academy of Sciences of the United States of America, 98(9), 5134–5139. https://doi.org/10.1073/pnas.081068398
   PubMed Web of Science ®Google Scholar
• Sadeghi, F., Asgari, M., Matloubi, M., Ranjbar, M., Karkhaneh Yousefi, N., Azari, T., & Zaki-Dizaji, M. (2020). Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: Review of radiosensitivity assays. Biological Procedures Online, 22(1), 23. https://doi.org/10.1186/s12575-020-00133-5
   PubMed Web of Science ®Google Scholar
• Samocha, K. E., Kosmicki, J. A., Karczewski, K. J., O’Donnell-Luria, A. H., Pierce-Hoffman, E., MacArthur, D. G., Neale, B.M., Daly, M. J. (2017). Regional missense constraint improves variant deleteriousness prediction. BioRxiv, 148353. https://doi.org/10.1101/148353
   Google Scholar
• Schwarz, J. M., Rödelsperger, C., Schuelke, M., & Seelow, D. (2010). MutationTaster evaluates disease-causing potential of sequence alterations. Nature Methods, 7(8), 575–576. https://doi.org/10.1038/nmeth0810-575
   PubMed Web of Science ®Google Scholar
• Shiozaki, E. N., Gu, L., Yan, N., & Shi, Y. (2004). Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: Implications for signaling. Molecular Cell, 14(3), 405–412. https://doi.org/10.1016/s1097-2765(04)00238-2
   PubMed Web of Science ®Google Scholar
• Silk, M., Petrovski, S., & Ascher, D. B. (2019). MTR-Viewer: Identifying regions within genes under purifying selection. Nucleic Acids Research, 47(W1), W121–W126. https://doi.org/10.1093/nar/gkz457
   PubMed Web of Science ®Google Scholar
• Silk, M., Pires, D. E. V., Rodrigues, C. H. M., D'Souza, E. N., Olshansky, M., Thorne, N., & Ascher, D. B. (2021). MTR3D: Identifying regions within protein tertiary structures under purifying selection. Nucleic Acids Research, 49(W1), W438–W445. https://doi.org/10.1093/nar/gkab428
   PubMed Web of Science ®Google Scholar
• Struewing, J. P., Tarone, R. E., Brody, L. C., Li, F. P., & Boice, J. D. (1996). BRCA1 mutations in young women with breast cancer. Lancet (London, England), 347(9013), 1493. https://doi.org/10.1016/s0140-6736(96)91732-8
   PubMed Web of Science ®Google Scholar
• Swanger, S. A., Chen, W., Wells, G., Burger, P. B., Tankovic, A., Bhattacharya, S., Strong, K. L., Hu, C., Kusumoto, H., Zhang, J., Adams, D. R., Millichap, J. J., Petrovski, S., Traynelis, S. F., & Yuan, H. (2016). Mechanistic insight into NMDA receptor dysregulation by rare variants in the GluN2A and GluN2B agonist binding domains. American Journal of Human Genetics, 99(6), 1261–1280. https://doi.org/10.1016/j.ajhg.2016.10.002
   PubMed Web of Science ®Google Scholar
• Tavtigian, S. V., Deffenbaugh, A. M., Yin, L., Judkins, T., Scholl, T., Samollow, P. B., de Silva, D., Zharkikh, A., & Thomas, A. (2006). Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. Journal of Medical Genetics, 43(4), 295–305. https://doi.org/10.1136/jmg.2005.033878
   PubMed Web of Science ®Google Scholar
• Traynelis, J., Silk, M., Wang, Q., Berkovic, S. F., Liu, L., Ascher, D. B., Balding, D. J., & Petrovski, S. (2017). Optimizing genomic medicine in epilepsy through a gene-customized approach to missense variant interpretation. Genome Research, 27(10), 1715–1729. https://doi.org/10.1101/gr.226589.117
   PubMed Web of Science ®Google Scholar
• Uversky, V. N., Oldfield, C. J., & Dunker, A. K. (2005). Showing your ID: Intrinsic disorder as an ID for recognition, regulation and cell signaling. Journal of Molecular Recognition: JMR, 18(5), 343–384. https://doi.org/10.1002/jmr.747
   PubMed Web of Science ®Google Scholar
• Venkitaraman, A. R. (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108(2), 171–182. https://doi.org/10.1016/s0092-8674(02)00615-3
   PubMed Web of Science ®Google Scholar
• Vitkup, D., Sander, C., & Church, G. M. (2003). The amino-acid mutational spectrum of human genetic disease. Genome Biology, 4(11), R72. https://doi.org/10.1186/gb-2003-4-11-r72
   PubMed Web of Science ®Google Scholar
• Vos, J., Gómez-García, E., Oosterwijk, J. C., Menko, F. H., Stoel, R. D., van Asperen, C. J., Jansen, A. M., Stiggelbout, A. M., & Tibben, A. (2012). Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees’ perception, the medical impact by the pathogenic or uninformative BRCA1/2‐result. Psycho-oncology, 21(1), 29–42. https://doi.org/10.1002/pon.1864
   PubMed Web of Science ®Google Scholar
• Williams, R. S., & Glover, J. M. (2003). Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. The Journal of Biological Chemistry, 278(4), 2630–2635. https://doi.org/10.1074/jbc.M210019200
   PubMed Web of Science ®Google Scholar
• Williams, R. S., Green, R., & Glover, J. M. (2001). Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nature Structural Biology, 8(10), 838–842. https://doi.org/10.1038/nsb1001-838
   PubMedGoogle Scholar
• Williams, R. S., Lee, M. S., Hau, D. D., & Glover, J. (2004). Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nature Structural & Molecular Biology, 11(6), 519–525. https://doi.org/10.1038/nsmb776
   PubMed Web of Science ®Google Scholar
• Yu, X., Chini, C. C. S., He, M., Mer, G., & Chen, J. (2003). The BRCT domain is a phospho-protein binding domain. Science (New York, N.Y.), 302(5645), 639–642. https://doi.org/10.1126/science.1088753
   PubMed Web of Science ®Google Scholar